Psychopathology II: Treatment, Depression, Bipolar Disorder, and ADHD

Two people report poor concentration. One has recently developed persistent low mood and disrupted sleep; the other has struggled with attention across settings since childhood. Similar symptoms can belong to different patterns. Treatment research asks not simply whether someone improves, but what improves, compared with what, for whom, and for how long.

Learning goals and Feynman practice

Explain psychotherapy and medication without treating them as opposites, distinguish depression from bipolar disorder, interpret placebo comparisons, and explain what ADHD treatment trials establish. Read a section, close it, and teach the mechanism to a beginner. Give a new example and one limitation. Repair your missing step before opening the answers. These are educational notes, not a personal treatment plan.

1. Treatment involves more than two competing boxes

Psychotherapy uses structured psychological methods and a therapeutic relationship to address difficulties. Psychopharmacology concerns medications and their effects. Care can also include educational support, family interventions, practical accommodations, social services, and brain-stimulation treatments in appropriate circumstances.

The choice depends on the condition, severity, preferences, previous response, co-occurring difficulties, access, and risks. Combined care can be useful; neither “talk” nor “medical” means that only one level of the person is affected.

Cognitive behavioural therapy

Aaron Beck helped develop cognitive therapy for depression; modern CBT includes multiple related approaches with cognitive and behavioural elements. It examines relationships among interpretations, feelings, actions, and circumstances.

Consider a fictional student who thinks, “One disappointing grade proves I fail at everything.” The thought increases hopelessness, withdrawal reduces opportunities for useful feedback, and the pattern continues. CBT might help examine the inference, test alternatives, and plan manageable actions. It is not simply replacing negative thoughts with cheerful claims or declaring real adversity imaginary.

Teach it back: Why might changing behaviour provide evidence that helps revise a belief, rather than waiting for the belief to change first?

2. What does psychotherapy efficacy mean?

Trials compare specified interventions with wait-list, usual care, attention controls, or another active treatment. These comparisons answer different questions. Wait-list improvement differences include effects of attention, expectation, support, and specific techniques.

A statement that therapy offers a universal “2:1 chance of improvement” is uninterpretable without an outcome, comparator, duration, and statistical measure. Odds, probabilities, and standardized effect sizes cannot be substituted for one another.

The therapeutic alliance includes collaboration, trust, and agreement about goals and tasks. It matters, but correlations between alliance and improvement can run in both directions: early improvement can strengthen the relationship. Effective care also depends on appropriate methods, competence, safety, and fit. Evidence does not justify saying qualifications, experience, or treatment duration never matter.

Teach-back check: if 60% improve with treatment and 40% with a control, what changed?

The absolute difference is 20 percentage points and the probability ratio is 1.5. The odds ratio is different again. These are invented teaching values; none establishes an individual guarantee or explains which treatment component caused the difference.

3. Depression: distinguish low mood from loss of pleasure

Dysphoria concerns an unpleasant or distressed mood. Anhedonia is reduced interest or pleasure; they are not synonyms. Major depressive disorder involves a sustained pattern of symptoms, including depressed mood or reduced interest, with associated features and significant impact. Assessment also considers duration, medical and substance-related causes, and any history of mania or hypomania.

Sleep, appetite, energy, movement, concentration, guilt, and self-worth can change. People need not show every symptom in the same way. A period of sadness or one checklist item does not establish the diagnosis.

Prevalence, age of onset, sex differences, and recurrence vary by population and definition. The outline’s 5%, age 30, two-to-threefold diagnosis ratio, and 70% recurrence figures should not be treated as universal constants. Recurrence risk also depends on previous episodes, residual symptoms, follow-up, and care.

Cognitive patterns and biological contributions

Beck’s negative triad describes negative interpretations of the self, world, and future. Such patterns can contribute to maintaining difficulty without explaining every cause. Attention tasks, including dot-probe measures, have measurement and reliability limits; a task score is not a diagnosis or a direct readout of a person’s beliefs.

Depression involves many genetic and environmental influences. Twin concordance is not heritability, and neither supplies a fixed personal risk.

The 2003 serotonin-transporter candidate-gene interaction report was influential, but later large studies did not support several historical candidate-gene and gene-by-environment hypotheses. [1] It is therefore misleading to teach the short allele as an established switch determining who becomes depressed after stress. This does not mean that genes or environmental adversity are irrelevant.

Teach it back: How can a specific gene claim fail replication while broader genetic contributions remain plausible?

4. Brain imaging: an association is not a treatment selector

Studies report differences in regions and networks including the subgenual anterior cingulate. Findings vary with task, sample, treatment history, and measurement. A group-average structural or activity difference is not a diagnostic scan.

Both psychotherapy and medication can be associated with changes in brain measurements. That does not prove that they operate through wholly separate pathways, or that each observed change caused recovery. Symptom change, practice, expectations, and other influences can also affect the measurement.

Research on predicting response from pretreatment imaging is promising but does not establish a routine, universally reliable scan choosing CBT versus medication. A predictor needs independent validation, useful accuracy, and evidence that using it improves decisions.

Teach-back check: why is predicting outcome in the original sample insufficient?

A model can fit sample-specific noise. Test it in new participants, compare it with simpler predictors, and evaluate whether its use changes care beneficially. Statistical association alone does not establish clinical usefulness.

5. Antidepressants and placebo: compare the right quantities

Medication classes include SSRIs, SNRIs, other antidepressants, tricyclics, and MAOIs. They differ in indications, adverse effects, interactions, and monitoring needs. Their actions do not establish that depression is simply a serotonin deficiency.

Placebo-group improvement includes natural fluctuation, regression toward the mean, expectations, supportive contact, and other changes. It is not identical to a pure placebo effect, which requires comparison with an appropriate no-treatment condition.

If a placebo group shows much of the treatment group’s average symptom improvement, it does not follow that the medication is ineffective or that most patients do not benefit. The randomized difference estimates an additional average effect under that trial’s conditions. Ratios of within-group changes are not the proportion of an individual’s benefit caused by placebo.

Some analyses found larger drug–placebo differences at higher baseline severity. Other large syntheses support average antidepressant efficacy across acute adult major-depression trials. [2] “Only very severe depression benefits” is too categorical. Clinical importance, acceptability, side effects, population, duration, and uncertainty all matter.

Antidepressants commonly take weeks to show their full benefit; they are not generally an immediate rescue for an acute crisis. [3] Medication changes and discontinuation require an individualized clinical plan, rather than conclusions drawn from a lecture statistic.

Longer-term outcomes

CBT can teach reusable skills, and some studies find enduring protection after treatment. Continued medication can also help prevent relapse for appropriate patients. Comparisons depend on whether medication is continued or stopped, how withdrawal and recurrence are distinguished, and what follow-up support is available. Neither approach guarantees no future episode.

6. Bipolar disorder: not simply depression alternating on a schedule

Bipolar disorders involve episodes of mania or hypomania and, depending on the diagnosis, depression. Episodes need not alternate predictably. Mania includes a marked change in mood and energy or activity with associated symptoms and substantial consequences; hypomania differs in severity and functional impact. Ordinary happiness or everyday mood shifts are not equivalent.

Treatment can include mood stabilizers such as lithium, selected antipsychotics, psychotherapy, and other supports. Valproate-related medications have specific risks and monitoring requirements; naming a drug is not a recommendation.

Antidepressants require particular caution and are not used alone in the standard bipolar treatment approach described by NIMH because of risks including mania or rapid cycling. [4] The history of elevated mood, energy, sleep need, and activity therefore matters when evaluating a depressive presentation.

Teach it back: Why does a treatment that can help one depressive condition need a different risk assessment in bipolar disorder?

7. ADHD: a developmental pattern across settings

ADHD involves persistent, impairing patterns of inattention and/or hyperactivity–impulsivity beginning in childhood. Presentations vary: some people are predominantly inattentive, so hyperactivity is not required in every case. Patterns must be considered across settings and in relation to developmental expectations. [5]

Girls, women, and people with less disruptive presentations can be missed. Diagnosis ratios vary by age, referral practices, and sample rather than providing a fixed biological ratio. Sleep difficulties, anxiety, depression, stress, and other conditions can also affect attention.

ADHD is associated with educational, occupational, relationship, and safety challenges, but outcomes vary. Comparing treated and untreated groups observationally is difficult because severity, resources, and access influence treatment selection. Poor outcomes are not inevitable, and co-occurring conditions need their own assessment.

Treatment can include medication, behavioural approaches, parent and school support, and practical accommodations. Benefits for a core symptom score and benefits for everyday functioning are related but distinct outcomes.

8. The MTA study: specify who, what, and when

The original MTA randomized 579 children aged 7–9.9 years with combined-type ADHD to 14 months of medication management, intensive behavioural treatment, their combination, or community care. [6]

Comparison	Main lesson	Limit
Structured medication management versus other conditions	Strong benefit for core symptoms during the trial.	A monitored protocol differs from every routine prescription.
Combined treatment	Can add value across some functional outcomes and treatment goals.	Not uniformly superior on every core symptom measure.
Behavioural treatment	Addresses routines, family and school practices, and functional demands.	Its effects depend on the outcome and intervention delivered.
Community care	Represents care outside the trial’s specified interventions.	Not a pure untreated placebo condition; participants could receive medication.

Combined care could achieve outcomes with lower average medication doses in that protocol. This is not an instruction to reduce a particular child’s dose. The randomized phase also does not establish lifelong superiority: later follow-up includes changing treatments and other influences outside the original assignment.

Teach it back: Why cannot results from this child sample be transferred automatically to adults or every ADHD presentation?

9. Non-prescribed stimulant use: survey rates are not efficacy evidence

The outline’s 7% figure requires a country, institution, survey period, and definition of use. Reported use among students does not establish better learning, durable academic gains, or safety in people without ADHD.

Feeling more alert is not the same as improving retention or grades. Non-prescribed use carries health and misuse risks and lacks individualized monitoring. The relevant lesson is to distinguish popularity, subjective experience, controlled cognitive outcomes, and clinical indication.

Retrieval workshop and spaced review

Explain dysphoria versus anhedonia, placebo response versus drug–placebo difference, and attention symptoms versus ADHD. Reconstruct the MTA table and identify the population and follow-up before interpreting its results.

Repair: a good therapeutic relationship makes methods and competence irrelevant

Collaboration matters, but appropriate techniques, assessment, competence, and safety also matter. An alliance–outcome correlation does not isolate the relationship as the only causal ingredient.

Repair: placebo improvement proves symptoms are imaginary

Symptoms and improvement can be real regardless of which mechanisms produce change. A placebo group combines several influences; the randomized contrast addresses an additional average treatment effect.

Apply: how would you evaluate a claim that a treatment works best?

Specify the diagnosis, participants, comparison, outcome, time horizon, harms, dropout, and uncertainty. Check whether the evidence is randomized and whether benefits transfer to functioning and persist after the trial.

Review tomorrow and in a week. Score each explanation: 0 for a label, 1 for a definition, 2 for a mechanism, example, and limitation. Repair the weakest explanation first.

One-minute explanation: Similar symptoms can reflect different clinical patterns. Psychotherapy, medication, and practical supports work within a broader care plan. Treatment evidence depends on comparisons, outcomes, populations, and time. Genetic and imaging associations do not independently diagnose or choose care. Depression, bipolar disorder, and ADHD require different histories and risk assessments, and no average result determines an individual’s response.

Sources and further reading

The supplied citations lacked a bibliography. These sources support current qualifications; the student scenarios and invented numerical example are teaching aids.

1. Border, R., et al. (2019). No support for historical candidate gene or candidate gene-by-interaction hypotheses for major depression.
2. Cipriani, A., et al. (2018). Comparative efficacy and acceptability of 21 antidepressant drugs.
3. NIMH. Depression.
4. NIMH. Bipolar disorder.
5. NIMH. ADHD: what you need to know.
6. MTA Cooperative Group (1999). A 14-month randomized clinical trial of treatment strategies for ADHD.